BACKGROUND AND AIMS: Treatment of oesophageal cancer depends on staging and the general health of the patient. In stages I-II b, as well as in some stage III diseases, surgical resection remains the therapy of choice for cure, but a curative approach is not possible in stage IV. In our hospital we give preoperative radio-chemotherapy to all patients with an oesophageal cancer T>1, Nx, M0. Therefore, the main purpose of the clinical staging of oesophageal cancer is the exclusion of M1 and T4 disease with infiltration into the tracheobronchial system or the aorta. The aim of the investigation was the assessment of positron emission tomography for detection of M1 disease. PATIENTS/ METHODS: Between 1998 and 2002, 84 patients with oesophageal cancer (64% squamous cell carcinoma and 36% adenocarcinoma) were enrolled into the study. Of these, 48.8% were operated on; 35.7% of the patients were not operated on, for oncological reasons, 7.1% for medical reasons, 3.6% chose not to be operated on, and, for unknown reasons, 4.8% were not operated on. RESULTS: Twenty-five patients had stage IV disease or additional, synchronous cancer of the head and neck ( n=2). As the only investigational procedure, positron emission tomography revealed M1 stage in 11 of 25 patients (44%). In 13/25 (52%) both computed tomography and positron emission tomography revealed stage IV disease. False positive results by positron emission tomography were observed in three patients. The sensitivity and specificity of positron emission tomography (PET) was 0.96 and 0.95, respectively. Most of the metastases detected by PET only, were localised within the neck, liver and bone. With regard to the 66 of 84 patients deemed medically fit for operation and without local infiltration into the tracheobronchial system (T4) PET as the only imaging procedure changed the therapeutic strategy in 11 of 66 (16.6%) patients with to M1 disease. CONCLUSION: Our results demonstrated clearly the impact of the PET scan for decision-making in patients with oesophageal carcinoma. PET should be performed prior to therapy with curative intention. However, addition of a computed tomography scan of the neck might reduce the rate of unexpected metastases detected by PET.
BACKGROUND AND AIMS: Treatment of oesophageal cancer depends on staging and the general health of the patient. In stages I-II b, as well as in some stage III diseases, surgical resection remains the therapy of choice for cure, but a curative approach is not possible in stage IV. In our hospital we give preoperative radio-chemotherapy to all patients with an oesophageal cancer T>1, Nx, M0. Therefore, the main purpose of the clinical staging of oesophageal cancer is the exclusion of M1 and T4 disease with infiltration into the tracheobronchial system or the aorta. The aim of the investigation was the assessment of positron emission tomography for detection of M1 disease. PATIENTS/ METHODS: Between 1998 and 2002, 84 patients with oesophageal cancer (64% squamous cell carcinoma and 36% adenocarcinoma) were enrolled into the study. Of these, 48.8% were operated on; 35.7% of the patients were not operated on, for oncological reasons, 7.1% for medical reasons, 3.6% chose not to be operated on, and, for unknown reasons, 4.8% were not operated on. RESULTS: Twenty-five patients had stage IV disease or additional, synchronous cancer of the head and neck ( n=2). As the only investigational procedure, positron emission tomography revealed M1 stage in 11 of 25 patients (44%). In 13/25 (52%) both computed tomography and positron emission tomography revealed stage IV disease. False positive results by positron emission tomography were observed in three patients. The sensitivity and specificity of positron emission tomography (PET) was 0.96 and 0.95, respectively. Most of the metastases detected by PET only, were localised within the neck, liver and bone. With regard to the 66 of 84 patients deemed medically fit for operation and without local infiltration into the tracheobronchial system (T4) PET as the only imaging procedure changed the therapeutic strategy in 11 of 66 (16.6%) patients with to M1 disease. CONCLUSION: Our results demonstrated clearly the impact of the PET scan for decision-making in patients with oesophageal carcinoma. PET should be performed prior to therapy with curative intention. However, addition of a computed tomography scan of the neck might reduce the rate of unexpected metastases detected by PET.
Authors: J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud Journal: N Engl J Med Date: 1997-07-17 Impact factor: 91.245
Authors: P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans Journal: J Clin Oncol Date: 2000-09-15 Impact factor: 44.544
Authors: W H Blahd; C V Brown; S A Khonsary; J B Farahi; N Quinones; J Y Ribe; J J Coyle; E C Glass; M A Mandelkern Journal: World J Surg Date: 1996-02 Impact factor: 3.352
Authors: Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Guy Bormans; Jan Balzarini; Gregor Verhoef; Luc Mortelmans; Peter Vandenberghe; Christine De Wolf-Peeters Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-25 Impact factor: 9.236
Authors: K Nygaard; S Hagen; H S Hansen; R Hatlevoll; R Hultborn; A Jakobsen; M Mäntyla; H Modig; E Munck-Wikland; B Rosengren Journal: World J Surg Date: 1992 Nov-Dec Impact factor: 3.352
Authors: Wayne Hofstetter; Stephen G Swisher; Arlene M Correa; Kenneth Hess; Joe B Putnam; Jaffer A Ajani; Marcelo Dolormente; Rhodette Francisco; Ritsuko R Komaki; Axbal Lara; Faye Martin; David C Rice; Arcenio J Sarabia; W Roy Smythe; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth Journal: Ann Surg Date: 2002-09 Impact factor: 12.969
Authors: Cuong P Duong; Helen Demitriou; Leann Weih; Anne Thompson; David Williams; Robert J S Thomas; Rodney J Hicks Journal: Eur J Nucl Med Mol Imaging Date: 2006-02-10 Impact factor: 9.236
Authors: Marinke Westerterp; Gerrit W Sloof; Otto S Hoekstra; Fiebo J W Ten Kate; Gerrit A Meijer; Johannes B Reitsma; Ronald Boellaard; J Jan B van Lanschot; Carla F M Molthoff Journal: J Cancer Res Clin Oncol Date: 2007-07-25 Impact factor: 4.553
Authors: B E Chatterton; I Ho Shon; A Baldey; N Lenzo; A Patrikeos; B Kelley; D Wong; J E Ramshaw; A M Scott Journal: Eur J Nucl Med Mol Imaging Date: 2008-10-18 Impact factor: 9.236